Mosanna Therapeutics

United States - Redwood City, CA

• 10/06/2025
• Series A
• $80,000,000

Mosanna Therapeutics is a clinical-stage biotech company pioneering a novel pharmaceutical approach to treating obstructive sleep apnea (OSA) with an easily administered nasal spray. Designed to help restore the body’s natural airway control during sleep, Mosanna’s lead therapy, MOS118, offers a drug-based alternative to traditional mechanical treatments and is currently being evaluated in a Phase 1 clinical trial. Founded in 2022, the company has raised more than $80 million from investors including Pivotal bioVenture Partners, EQT Life Sciences, Forbion, Norwest, Broadview Ventures, Forty51 Ventures, Supermoon Capital and High-Tech Gründerfonds (HTGF). Mosanna has offices in Redwood City, California and Basel, Switzerland.

Related People

David Weber, PhDFounder

United States - Prosper, Texas

Chief executive with a track record of product development across pharmaceutical, biotechnology, medical device and consumer products. Built and led high-performing organizations across both public and private sectors. History of entering new therapeutic areas and establishing strong technical, clinical, regulatory and market knowledge to drive product development and value creation.

LinkedIn https://www.linkedin.com/in/david-weber-phd-227b089/